Ulrik Lassen
About
Ulrik Lassen is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology.
According to data from OpenAlex, Ulrik Lassen has authored 253 papers receiving a total of 4.9k indexed citations (citations by other indexed papers that have themselves been cited), including 118 papers in Oncology, 104 papers in Pulmonary and Respiratory Medicine and 80 papers in Molecular Biology. Recurrent topics in Ulrik Lassen's work include Lung Cancer Treatments and Mutations (60 papers), Glioma Diagnosis and Treatment (56 papers) and Cancer Genomics and Diagnostics (40 papers). Ulrik Lassen is often cited by papers focused on Lung Cancer Treatments and Mutations (60 papers), Glioma Diagnosis and Treatment (56 papers) and Cancer Genomics and Diagnostics (40 papers). Ulrik Lassen collaborates with scholars based in Denmark, United States and Germany. Ulrik Lassen's co-authors include Hans Skovgaard Poulsen, Morten Mau‐Sørensen, Heine H. Hansen, Benedikte Hasselbalch, Gedske Daugaard, Shivaani Kummar, Kell Østerlind, Bengt Bergman, Marie‐Thérése Stockhausen and P Dombernowsky and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.
In The Last Decade
Ulrik Lassen
239 papers receiving 4.9k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ulrik Lassen Denmark | 36 | 2.2k | 1.7k | 1.6k | 1.0k | 933 | 253 | 4.9k | ||
| Maurizio Martini Italy | 44 | 1.9k 0.9× | 2.3k 1.4× | 1.1k 0.7× | 1.3k 1.3× | 1.3k 1.4× | 281 | 6.5k | ||
| Petr Kavan Canada | 29 | 1.5k 0.7× | 1.0k 0.6× | 1.1k 0.7× | 876 0.9× | 2.0k 2.2× | 141 | 4.4k | ||
| Nils D. Arvold United States | 26 | 1.3k 0.6× | 605 0.4× | 1.5k 1.0× | 709 0.7× | 1.1k 1.2× | 67 | 3.3k | ||
| Núria Viñolas Spain | 33 | 1.5k 0.7× | 1.6k 1.0× | 1.5k 0.9× | 1.2k 1.2× | 1.0k 1.1× | 123 | 4.3k | ||
| Kan Yonemori Japan | 38 | 3.8k 1.7× | 1.4k 0.8× | 1.9k 1.2× | 898 0.9× | 366 0.4× | 392 | 6.2k | ||
| Margaret Dugan United States | 29 | 2.5k 1.1× | 1.9k 1.1× | 1.3k 0.8× | 1.4k 1.4× | 2.2k 2.4× | 71 | 6.2k | ||
| Carlo L. Bello United States | 27 | 3.1k 1.4× | 3.1k 1.8× | 4.1k 2.6× | 1.5k 1.5× | 543 0.6× | 54 | 7.5k | ||
| Marcia S. Brose United States | 44 | 4.5k 2.0× | 3.6k 2.1× | 2.1k 1.3× | 1.4k 1.4× | 506 0.5× | 187 | 11.5k | ||
| Peter Langmuir United States | 30 | 1.8k 0.8× | 1.3k 0.8× | 1.6k 1.1× | 507 0.5× | 384 0.4× | 56 | 4.7k | ||
| Alexander Laird United States | 32 | 1.7k 0.8× | 2.7k 1.6× | 1.2k 0.8× | 745 0.7× | 434 0.5× | 97 | 4.9k |
Countries citing papers authored by Ulrik Lassen
Since
Specialization
Citations
This map shows the geographic impact of Ulrik Lassen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ulrik Lassen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ulrik Lassen more than expected).
Fields of papers citing papers by Ulrik Lassen
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Ulrik Lassen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ulrik Lassen. The network helps show where Ulrik Lassen may publish in the future.
Co-authorship network of co-authors of Ulrik Lassen
This figure shows the co-authorship network connecting the top 25 collaborators of Ulrik Lassen. A scholar is included among the top collaborators of Ulrik Lassen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ulrik Lassen. Ulrik Lassen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Yde, Christina W., A. Schmidt, Martin Højgaard, et al.. (2026). Immune Cell Modulation of Patient-Matched Organoid Drug Response in Precision Cancer Medicine Platform. Cells. 15(3). 259–259.
2.
Henriksen, O., Benedikte Hasselbalch, Hans Skovgaard Poulsen, et al.. (2024). Magnetic resonance imaging and o -(2-[18F]fluoroethyl)-l -tyrosine positron emission tomography for early response assessment of nivolumab and bevacizumab in patients with recurrent high-grade astrocytic glioma. Neuro-Oncology Advances. 6(1). vdae178–vdae178.
3.
Draghi, Arianna, Annie Borch, Filip Mundt, et al.. (2024). Nivolumab Reaches Brain Lesions in Patients with Recurrent Glioblastoma and Induces T-cell Activity and Upregulation of Checkpoint Pathways. Cancer Immunology Research. 12(9). 1202–1220.
4.
Debnath, Olivia, Naveed Ishaque, Jane Skjøth‐Rasmussen, et al.. (2024). Immunotherapy drives mesenchymal tumor cell state shift and TME immune response in glioblastoma patients. Neuro-Oncology. 26(8). 1453–1466.
5.
Berg, Tobias, et al.. (2023). 391P Detrimental effect on overall survival of CDK4/6 inhibitor dose reduction if immortal time bias is considered. Annals of Oncology. 34. S344–S345.
6.
Drilon, Alexander, Lin Shen, François Doz, et al.. (2023). 668P Efficacy and safety of larotrectinib in a pooled analysis of patients (Pts) with tropomyosin receptor kinase (TRK) fusion cancer. Annals of Oncology. 34. S470–S470.
7.
Gelderblom, Hans, Anders Edsjö, Ulrik Lassen, et al.. (2023). 1711P The DRUP-like clinical trials family: A distributed European trial network for equitable access to precision medicine. Annals of Oncology. 34. S933–S934.
8.
Løppenthin, Katrine, Pernille Envold Bidstrup, Elisabeth Wreford Andersen, et al.. (2023). Impact of multimorbidity and polypharmacy on mortality after cancer: a nationwide registry-based cohort study in Denmark 2005–2017. Acta Oncologica. 62(12). 1653–1660.
9.
Rafaeva, Maria, Edward R. Horton, Chris D. Madsen, et al.. (2021). Modeling Metastatic Colonization in a Decellularized Organ Scaffold‐Based Perfusion Bioreactor. Advanced Healthcare Materials. 11(1). e2100684–e2100684.
10.
Borch, Annie, Morten Hansen, Arianna Draghi, et al.. (2020). Common phenotypic dynamics of tumor-infiltrating lymphocytes across different histologies upon checkpoint inhibition: impact on clinical outcome. Cytotherapy. 22(4). 204–213.
11.
Ramskov, Sofie, Theo Sturm, Annie Borch, et al.. (2019). HLA-C restricted neoepitopes contribute significantly to the immune recognition of cancer. Technical University of Denmark, DTU Orbit (Technical University of Denmark, DTU).
12.
Morgensztern, Daniel, Nina Karaseva, Enriqueta Felip, et al.. (2019). An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancer. Lung Cancer. 136. 74–79.
13.
Rohrberg, Kristoffer Staal, Lise Barlebo Ahlborn, Ane Yde Schmidt, et al.. (2018). Copenhagen Prospective Personalized Oncology (CoPPO)—Clinical Utility of Using Molecular Profiling to Select Patients to Phase I Trials. Clinical Cancer Research. 25(4). 1239–1247.
14.
Skjøth‐Rasmussen, Jane, Jannick Brennum, Oľga Østrup, et al.. (2017). GENE-50. GENOMIC PROFILING AND PRECISION MEDICINE IN GLIOBLASTOMA - A PROSPECTIVE STUDY. Neuro-Oncology. 19(suppl_6). vi103–vi103.
15.
Lassen, Ulrik, Didier Meulendijks, L.L. Siu, et al.. (2014). A Phase I Monotherapy Study of RG7212, a First-in-Class Monoclonal Antibody Targeting TWEAK Signaling in Patients with Advanced Cancers. Clinical Cancer Research. 21(2). 258–266.
16.
Spindler, Karen‐Lise Garm, Morten Mau‐Sørensen, Niels Pallisgaard, et al.. (2013). Phase II trial of temsirolimus alone and in combination with irinotecan forKRASmutant metastatic colorectal cancer: Outcome and results ofKRASmutational analysis in plasma. Acta Oncologica. 52(5). 963–970.
17.
Møller, Søren, Kirsten Grunnet, Steinbjørn Hansen, et al.. (2012). A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy. Acta Oncologica. 51(6). 797–804.
18.
Poulsen, Hans Skovgaard, Kirsten Grunnet, Morten Mau‐Sørensen, et al.. (2008). Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours. Acta Oncologica. 48(1). 52–58.
19.
Molife, R., James Lee, Daniel Petrylak, et al.. (2007). A phase I study of oral belinostat (PXD101) in patients with advanced solid tumors.. Molecular Cancer Therapeutics. 6.
20.
Daugaard, Gedske, Ulrik Lassen, Peter Bie, et al.. (2004). Natriuretic Peptides in the Monitoring of Anthracycline Induced Reduction in Left Ventricular Ejection Fraction. European Journal of Heart Failure. 7(1). 87–93.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Maurizio Martini Breakdown of academic impact, for papers by Petr Kavan Breakdown of academic impact, for papers by Nils D. Arvold Breakdown of academic impact, for papers by Núria Viñolas Breakdown of academic impact, for papers by Kan Yonemori Breakdown of academic impact, for papers by Margaret Dugan Breakdown of academic impact, for papers by Carlo L. Bello Breakdown of academic impact, for papers by Marcia S. Brose Breakdown of academic impact, for papers by Peter Langmuir Breakdown of academic impact, for papers by Alexander Laird